Duxin Sun

8518984, Aug 27, 2013

Nov 12, 2010

12/945511

Shaomeng Wang - Saline MI, US
Shanghai Yu - Ann Arbor MI, US
Wei Sun - Ann Arbor MI, US
Sanjeev Kumar - Ann Arbor MI, US
Duxin Sun - Ann Arbor MI, US
Peng Zou - Ann Arbor MI, US
Donna McEachern - Ann Arbor MI, US
Yujun Zhao - Ann Arbor MI, US

The Regents of the University of Michigan - Ann Arbor MI

C07D 487/10
A61K 31/4015

514409, 548406

Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.

20050059719, Mar 17, 2005

Aug 23, 2004

10/924043

Sherif Badawy - Dayton NJ, US
Munir Hussain - Belle Mead NJ, US
Duxin Sun - Dublin OH, US

A61K031/42

514379000

An oral solid dosage formulation is provided which contains a Factor Xa inhibitor for which oral bioavailability is not reduced by co-administration of antacids, H2 antagonists and proton pump inhibitors. Such solid dosage formulation includes the Factor Xa inhibitor of the structure, a pharmaceutically acceptable carrier, and an acid component, such as tartaric acid, whereby upon ingestion of the oral solid dosage formulation, the acid component increases solubility of the Factor Xa inhibitor in the local environment of the dissolving solid dosage formulation resulting in an otherwise lower degree of supersaturation of the Factor Xa inhibitor in such environment, than if the acid were not present. The result is that precipitation of the Factor Xa inhibitor in the form of its insoluble free base is minimized during dissolution of the Factor Xa inhibitor thereby increasing its oral bioavailability. A method for enhancing bioavailability of the Factor Xa inhibitor is also provided wherein an acid such as tartaric acid is incorporated with the solid dosage pharmaceutical carrier for the Factor Xa inhibitor.

20060276418, Dec 7, 2006

May 12, 2006

11/432901

Guisheng Zhang - Columbus OH, US
Lanyan Fang - Columbus OH, US
Peng Wang - Columbus OH, US
Duxin Sun - Dublin OH, US

The Ohio State University Research Foundation - Columbus OH

A61K 31/704
C07H 15/24

514034000, 536006400

Daunorubicin (“DNR”) compounds synthesized with uncommon sugars exhibit enhanced effectiveness in treating various drug-resistant cancers.

20080312162, Dec 18, 2008

Oct 7, 2005

11/664034

Duxin Sun - Dublin OH, US
Peng George Wang - Columbus OH, US
Edward Martin, JR. - Delaware OH, US

THE OHIO STATE UNIVERSITY - Columbus OH

A61K 31/70
A61P 35/04

514 23

Methods for the targeted activation of prodrugs by enzymes, which cleave a linkage between a carbohydrate conjugate and a drug. Means to target the activation of prodrugs to specific cells by linking the enzyme to an antibody molecule. Carbohydrate conjugates of geldanamycin.

20090234225, Sep 17, 2009

Jan 12, 2009

12/352408

Edward W. Martin - Delaware OH, US
Ronald X. Xu - Columbus OH, US
Duxin Sun - Ann Arbor MI, US
Stephen P. Povoski - Dublin OH, US
Joseph Pierre Heremans - Upper Arlington OH, US
Robert Lee - Hilliard OH, US
Vish V. Subramaniam - Westerville OH, US
Claudia Turro - Powell OH, US

The Ohio State University Research Foundation - Columbus OH

A61B 6/00
A61K 49/00

600431, 424 96

Exemplary embodiments include systems, methods, and compositions for the intra-operative detection of target tissue. At least one embodiment includes a fluorescence detection instrument that may be used for intra-operative detection of a fluorescent targeting agent, its binding site, and its interaction within cancer tissues. An exemplary embodiment is highly sensitive to the local deposition of fluorescence agents even at a low concentration. In at least one embodiment, the system includes a handheld navigation instrument that is usable to excite, detect, and report the fluorescent deposition of the targeting agent in real-time. In alternative embodiments, the system includes a wearable unit to excite, detect, and visually report the fluorescent deposition of the targeting agent to the user. The wearable unit includes eyewear that allow the user to perform image-guided surgery based on the near real-time fluorescence detection of the fluorescent targeting agent.

20100249231, Sep 30, 2010

Nov 10, 2008

12/741430

Duxin Sun - Ann Arbor MI, US
Tao Zhang - Ann Arbor MI, US

THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION - Columbus OH

A61K 31/19
C12N 5/02
C07C 59/00
C12Q 1/02

514557, 435375, 562461, 435 29

A novel Hsp90 inhibitor that disrupts protein-protein interaction in a Hsp90 superchaperone complex without blocking ATP binding and methods for treating diseases such as pancreatic cancer are disclosed.

20120035457, Feb 9, 2012

Aug 15, 2011

13/210293

Vishwanath Subramaniam - Westerville OH, US
Joseph West - Richwood OH, US
Jennifer McFerran Brock - Anchorage AK, US
Emily Sequin - Columbus OH, US
Duxin Sun - Ann Arbor MI, US
Peng Zou - Walkersville MD, US

THE OHIO STATE UNIVERSITY - Columbus OH

A61B 5/053
A61B 5/05
A61N 2/02

600409, 600547, 600 13, 600425

Differences of electromagnetic (EM) properties between healthy and cancerous tissues allow detection of abnormal conditions occurring in a tissue of an animal, for example, intra-operative cancer detection. By using a time-varying EM field, electrical eddy currents are generated in the tissue sample, and assessed using phase-sensitive detection. In some aspects, a change in phase shift between the voltage in a receiver coil and the voltage in a driver coil provide a direct and immediate indication of differences in EM properties of specimens.

20120189539, Jul 26, 2012

Jan 24, 2012

13/356763

Shaomeng Wang - Saline MI, US
Haibin Zhou - Ann Arbor MI, US
Jianfang Chen - Ann Arbor MI, US
Angelo Aguilar - Ann Arbor MI, US
Jennifer L. Meagher - Plymouth MI, US
Duxin Sun - Ann Arbor MI, US
Chao-Yie Yang - Ann Arbor MI, US
Liu Liu - Ann Arbor MI, US
Longchuan Bai - Ann Arbor MI, US
Donna McEachem - Ann Arbor MI, US
Jeanne Stuckey - Fenton MI, US
Xiaoqin Li - Ann Arbor MI, US

THE REGENTS OF UNIVERSITY OF MICHIGAN - Ann Arbor MI

A61K 51/00
A61K 31/5377
A61K 31/496
C07D 413/14
C07D 403/12
C07D 401/14
C07D 403/10
C07D 405/10
A61P 35/00
A61K 31/5513
C07D 471/04

424 111, 51421018, 5142102, 514218, 5142365, 51425211, 51425304, 51425309, 51425401, 5142541, 540575, 544121, 544357, 544362, 544364, 544372, 544379

Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed.